Connect with us

Technology

ZIM Reports Financial Results for the Second Quarter of 2024; Raising Full Year 2024 Guidance

Published

on

Reported Revenues of $1.93 Billion, Net Income of $373 Million, Adjusted EBITDA1 of $766 Million and Adjusted EBIT of $488 Million2; Achieved Adjusted EBITDA and Adjusted EBIT Margins of 40% and 25%, Respectively

Achieved 11% Volume Growth with Record Carried Volume of 952 Thousand TEUs

Increased Full Year 2024 Guidance to Adjusted EBITDA of $2.6 Billion to $3.0 Billion and Adjusted EBIT of $1.45 Billion to $1.85 Billion3

Declared Dividend of $112 million, or $0.93 per Share

HAIFA, Israel, Aug. 19, 2024 /PRNewswire/ — ZIM Integrated Shipping Services Ltd. (NYSE: ZIM), (“ZIM” or the “Company”) a global container liner shipping company, announced today its consolidated results for the three and six months ended June 30, 2024.

Second Quarter 2024 Highlights

Net income for the second quarter was $373 million (compared to a net loss of $213 million in the second quarter of 2023), or diluted earnings per share of $3.084 (compared to diluted loss per share of $1.79 in the second quarter of 2023).
Adjusted EBITDA1 for the second quarter was $766 million, a year-over-year increase of 179%.
Operating income (EBIT) for the second quarter was $468 million, compared to operating loss of $168 million in the second quarter of 2023.
Adjusted EBIT1 for the second quarter was $488 million, compared to Adjusted EBIT loss of $147 million in the second quarter of 2023.
Total revenues for the second quarter were $1,933 million, a year-over-year increase of 48%.
Carried volume in the second quarter was 952 thousand TEUs, a year-over-year increase of 11%.
Average freight rate per TEU in the second quarter was $1,674, a year-over-year increase of 40%.
Net debt1 of $3.25 billion as of June 30, 2024, compared to $2.31 billion as of December 31, 2023; net leverage ratio1 of 2.0x at June 30, 2024, compared to 2.2x as of December 31, 2023.

Eli Glickman, ZIM President & CEO, stated, “We are pleased with our strong second quarter performance, highlighted by outstanding strategic execution that led to record high carried volume, representing 11% growth year-over-year. The steps we have taken to upscale our capacity and enhance our cost structure continued to drive strong financial results. We generated net income of $373 million, as we drew on our differentiated strategy and agility while capitalizing on sustained market strength. Aligned with our prioritization of returning capital to shareholders, we declared a dividend of $0.93 per share, or $112 million, representing 30% of second quarter net income.”

Mr. Glickman added, “During the quarter, we benefitted from ZIM’s strategic decision to increase the Company’s spot market exposure in the Transpacific trade. This has enabled us to capture significant upside in a rate environment that has been elevated for longer than anticipated. We expect our results in the second half of 2024 to be better than in the first half of the year, driven by continued supply pressure from the Red Sea crisis, combined with current favorable demand trends. As a result, we have significantly increased our full year 2024 guidance and today forecast full year Adjusted EBITDA between $2.6 billion and $3.0 billion and Adjusted EBIT between $1.45 billion and $1.85 billion.”

Mr. Glickman concluded, “While market fundamentals still signal supply growth significantly outpacing demand, we are confident that we have built a resilient business with a transformed fleet. By year’s end, our ongoing newbuild program will be complete, as we receive delivery of the remaining eight out of 46 modern, fuel-efficient containerships that we secured, including 28 LNG-powered vessels. We are on track to achieve our double-digit volume growth target in 2024 and well positioned to drive profitable growth ahead.”

 

Summary of Key Financial and Operational Results

 

Q2-24

       Q2-23    

      H1-24    

     H1-23    

Carried volume (K-TEUs)…………………………..

952

860

1,799

1,629

Average freight rate ($/TEU)………………………

1,674

1,193

1,569

1,286

Total revenues ($ in millions)………………………

1,933

1,310

3,495

2,684

Operating income (loss) (EBIT) ($ in millions). 

468

(168)

635

(182)

Profit (loss) before income tax ($ in millions)..

375

(272)

471

(337)

Net income (loss) ($ in millions)………………….

373

(213)

465

(271)

Adjusted EBITDA1 ($ in millions)…………………

766

275

1,193

648

Adjusted EBIT1 ($ in millions)……………………..

488

(147)

655

(160)

Net income (loss) margin (%)……………………..

19

(16)

13

(10)

Adjusted EBITDA margin (%)……………………..

40

21

34

24

Adjusted EBIT margin (%)………………………….

25

(11)

19

(6)

Diluted earnings (loss) per share ($)……………         

3.08

(1.79)

3.83

(2.29)

Net cash generated from operating activities
($ in millions)……………………………………………

777

347

1,103

520

Free cash flow1 ($ in millions)…………………….

712

321

1,015

463

 
 
 
 
 
 

JUN-30-24

DEC-31-23

 
 

Net debt1 ($ in millions)……………………………..

3,245

2,309

 
 

 

Financial and Operating Results for the Second Quarter Ended June 30, 2024
Total revenues were $1.93 billion for the second quarter of 2024, compared to $1.31 billion for the second quarter of 2023, mainly driven by the increase in freight rates and carried volume.

ZIM carried 952 thousand TEUs in the second quarter of 2024, compared to 860 thousand TEUs in the second quarter of 2023. The average freight rate per TEU was $1,674 for the second quarter of 2024, compared to $1,193 for the second quarter of 2023.

Operating income (EBIT) for the second quarter of 2024 was $468 million, compared to operating loss of $168 million for the second quarter of 2023. The increase was driven primarily by the above-mentioned increase in revenues.

Net income for the second quarter of 2024 was $373 million, compared to net loss of $213 million for the second quarter of 2023, also mainly driven by the above-mentioned increase in revenues.

Adjusted EBITDA for the second quarter of 2024 was $766 million, compared to $275 million for the second quarter of 2023. Adjusted EBIT was $488 million for the second quarter of 2024, compared to Adjusted EBIT loss of $147 million for the second quarter of 2023. Adjusted EBITDA and Adjusted EBIT margins for the second quarter of 2024 were 40% and 25%, respectively. This compares to 21% and -11% for the second quarter of 2023, respectively.

Net cash generated from operating activities was $777 million for the second quarter of 2024, compared to $347 million for the second quarter of 2023.

Financial and Operating Results for the Six Months Ended June 30, 2024
Total revenues were $3.49 billion for the first half of 2024, compared to $2.68 billion for the first half of 2023, primarily driven by both an increase in freight rates and carried volume.

ZIM carried 1,799 thousand TEUs in the first half of 2024, compared to 1,629 thousand TEUs in the first half of 2023. The average freight rate per TEU was $1,569 for the first half of 2024, compared to $1,286 for the first half of 2023.

Operating income (EBIT) for the first half of 2024 was $635 million, compared to operating loss of $182 million for the first half of 2023. The increase in operating income for the first half of 2024 was primarily driven by the above-mentioned increase in revenues.

Net income for the first half of 2024 was $465 million, compared to net loss of $271 million for the first half of 2023, also mainly driven by the above-mentioned increase in revenues.

Adjusted EBITDA was $1,193 million for the first half of 2024, compared to $648 million for the first half of 2023. Adjusted EBIT was $655 million for the first half of 2024, compared to Adjusted EBIT loss of $160 million for the first half of 2023. Adjusted EBITDA and Adjusted EBIT margins for the first half of 2024 were 34% and 19%, respectively. This compares to 24% and -6% for the first half of 2023.

Net cash generated from operating activities was $1,103 million for the first half of 2024, compared to $520 million for the first half of 2023.

Liquidity, Cash Flows and Capital Allocation
ZIM’s total cash position (which includes cash and cash equivalents and investments in bank deposits and other investment instruments) decreased by $351 million from $2.69 billion as of December 31, 2023 to $2.34 billion as of June 30, 2024. Capital expenditures totaled $66 million for the second quarter of 2024, compared to $26 million for the second quarter of 2023. Net debt position as of June 30, 2024 was $3.25 billion, compared to $2.31 billion, as of December 31, 2023, an increase of $936 million. ZIM’s net leverage ratio as of June 30, 2024, was 2.0x, compared to 2.2x as of December 31, 2023.

Second Quarter 2024 Dividend
In accordance with the Company’s dividend policy, the Company’s Board of Directors declared a cash dividend of approximately $112 million, or $0.93 per ordinary share, reflecting approximately 30% of second quarter 2024 net income. The dividend will be paid on September 5, 2024, to holders of ZIM ordinary shares as of August 29, 2024.

All future dividends are subject to the discretion of Company’s Board of Directors and to the restrictions provided by Israeli law.

Use of Non-IFRS Measures in the Company’s 2024 Guidance
A reconciliation of the Company’s non-IFRS financial measures included in its full-year 2024 guidance to corresponding IFRS measures is not available on a forward-looking basis. In particular, the Company has not reconciled its Adjusted EBITDA and Adjusted EBIT because the various reconciling items between such non-IFRS financial measures and the corresponding IFRS measures cannot be determined without unreasonable effort due to the uncertainty regarding, and the potential variability of, the future costs and expenses for which the Company adjusts, the effect of which may be significant, and all of which are difficult to predict and are subject to frequent change.

Updated Full-Year 2024 Guidance
The Company increased its guidance for the full year of 2024 and now expects to generate Adjusted EBITDA between $2.6 billion and $3.0 billion and Adjusted EBIT between $1.45 billion and $1.85 billion. Previously, the Company expected to generate Adjusted EBITDA between $1.15 billion and $1.55 billion and Adjusted EBIT between zero and $400 million.

Conference Call Details
Management will host a conference call and webcast (along with a slide presentation) to review the results and provide a corporate update today at 8:00 AM ET.

To access the live conference call by telephone, please dial the following numbers: United States (toll free) +1-800-715-9871 or +1-646-307-1963; Israel +972-3-376-1144 or UK/international +44-20-3481-4247, and reference conference ID: 3054682 or the conference name. The call (and slide presentation) will be available via live webcast through ZIM’s website, located at the following link. Following the conclusion of the call, a replay of the conference call will be available on the Company’s website.

About ZIM
Founded in Israel in 1945, ZIM (NYSE: ZIM) is a leading global container liner shipping company with established operations in more than 90 countries serving approximately 33,000 customers in over 300 ports worldwide. ZIM leverages digital strategies and a commitment to ESG values to provide customers innovative seaborne transportation and logistics services and exceptional customer experience. ZIM’s differentiated global-niche strategy, based on agile fleet management and deployment, covers major trade routes with a focus on select markets where the company holds competitive advantages. Additional information about ZIM is available at www.ZIM.com.

Forward-Looking Statements
The following information contains, or may be deemed to contain forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about the Company, may include projections of the Company’s future financial results, its anticipated growth strategies and anticipated trends in its business. These statements are only predictions based on the Company’s current expectations and projections about future events or results. There are important factors that could cause the Company’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause such differences include, but are not limited to: market changes in freight, bunker, charter and other rates or prices (including as a result of the continued situation in the Red Sea), supply-demand fluctuations in the containerized shipping market, new legislation or regulation affecting the Company’s operations, new competition and changes in the competitive environment, our ability to achieve cost savings or expense reductions, the outcome of legal proceedings to which the Company is a party, global, regional and/or local political instability, including the ongoing war between Israel and Hamas, the increased tension between Israel and Iran and its proxies, in particular the ongoing hostilities between Israel and Hezbollah, inflation rate fluctuations, capital markets fluctuations and other risks and uncertainties detailed from time to time in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including under the caption “Risk Factors” in its 2023 Annual Report filed with the SEC on March 13, 2024. 

Although the Company believes the expectations reflected in the forward-looking statements contained herein are reasonable, it cannot guarantee future results, level of activity, performance or achievements. Moreover, neither the Company nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. The Company assumes no duty to update any of these forward-looking statements after the date hereof to conform its prior statements to actual results or revised expectations, except as otherwise required by law.

The Company prepares its financial statements in accordance with International Financial Reporting Standards (IFRS), as issued by the International Accounting Standards Board (IASB).

Use of Non-IFRS Financial Measures
The Company presents non-IFRS measures as additional performance measures as the Company believes that it enables the comparison of operating performance between periods on a consistent basis. These measures should not be considered in isolation, or as a substitute for operating income, any other performance measures, or cash flow data, which were prepared in accordance with Generally Accepted Accounting Principles as measures of profitability or liquidity. Please note that Adjusted EBITDA does not take into account debt service requirements or other commitments, including capital expenditures, and therefore, does not necessarily indicate the amounts that may be available for the Company’s use. In addition, the non-IFRS financial measures presented by the Company may not be comparable to similarly titled measures reported by other companies due to differences in the way these measures are calculated.

Adjusted EBITDA is a non-IFRS financial measure which we define as net income (loss) adjusted to exclude financial expenses (income), net, income taxes, depreciation and amortization in order to reach EBITDA, and further adjusted, as applicable, to exclude impairment of assets, non-cash charter hire expenses, capital gains (losses) beyond the ordinary course of business and expenses related to legal contingencies.

Adjusted EBIT is a non-IFRS financial measure which we define as net income (loss) adjusted to exclude financial expenses (income), net and income taxes, in order to reach our results from operating activities, or EBIT, and further adjusted, as applicable, to exclude impairment of assets, non-cash charter hire expenses, capital gains (losses) beyond the ordinary course of business and expenses related to legal contingencies.

Free cash flow is a non-IFRS financial measure which we define as net cash generated from operating activities minus capital expenditures, net.

Net debt is a non-IFRS financial measure which we define as face value of short- and long-term debt, minus cash and cash equivalents, bank deposits and other investment instruments.  We refer to this measure as net cash when cash and cash equivalents, bank deposits and other investment instruments exceed the face value of short- and long-term debt.

Net leverage ratio is a non-IFRS financial measure which we define as net debt (see above) divided by Adjusted EBITDA for the last twelve-month period. When our net debt is less than zero, we report the net leverage ratio as zero.

See the reconciliation of net income to Adjusted EBIT and Adjusted EBITDA and net cash generated from operating activities to free cash flow in the tables provided below.

Investor Relations:
Elana Holzman
ZIM Integrated Shipping Services Ltd.
+972-4-865-2300
holzman.elana@zim.com

Leon Berman
The IGB Group
212-477-8438
lberman@igbir.com

Media:
Avner Shats
ZIM Integrated Shipping Services Ltd.
+972-4-865-2520
shats.avner@zim.com

 

CONSOLIDATED BALANCE SHEET (Unaudited)

(U.S. dollars in millions)

 

            June 30         

December 31

 

2024

2023

2023

 
 
 
 

Assets

 
 
 

Vessels

4,917.2

5,005.4

3,758.9

Containers and handling equipment

906.7

1,209.8

792.9

Other tangible assets

91.8

124.3

85.2

Intangible assets

105.7

98.1

102.0

Investments in associates 

28.4

29.3

26.4

Other investments

772.0

1,354.2

908.7

Other receivables

76.6

111.6

97.9

Deferred tax assets

2.5

2.5

2.6

Total non-current assets

6,900.9

7,935.2

5,774.6

 
 
 
 

Inventories

187.7

174.1

179.3

Trade and other receivables

1,030.9

671.0

596.5

Other investments

699.1

863.0

874.1

Cash and cash equivalents

889.8

1,040.3

921.5

Total current assets

2,807.5

2,748.4

2,571.4

Total assets

9,708.4

10,683.6

8,346.0

 
 
 
 

Equity

 
 
 

Share capital and reserves

2,016.7

1,994.8

2,017.5

Retained earnings

872.4

2,858.3

437.2

Equity attributable to owners of the Company

2,889.1

4,853.1

2,454.7

Non-controlling interests

2.4

2.0

3.3

Total equity

2,891.5

4,855.1

2,458.0

 
 
 
 

Liabilities

 
 
 

Lease liabilities

4,000.1

3,230.4

3,244.1

Loans and other liabilities

65.2

83.0

73.6

Employee benefits

42.5

42.4

46.1

Deferred tax liabilities

5.7

79.0

6.1

Total non-current liabilities

4,113.5

3,434.8

3,369.9

 
 
 
 

Trade and other payables

610.3

561.8

566.4

Provisions

87.9

53.4

60.7

Contract liabilities

475.1

208.4

198.1

Lease liabilities

1,481.9

1,522.1

1,644.7

Loans and other liabilities

48.2

48.0

48.2

Total current liabilities

2,703.4

2,393.7

2,518.1

Total liabilities

6,816.9

5,828.5

5,888.0

Total equity and liabilities

9,708.4

10,683.6

8,346.0

 

 

CONSOLIDATED INCOME STATEMENTS (Unaudited)

(U.S. dollars in millions, except per share data)

 

Six months
ended June 30

Three months
ended June 30

Year ended
December 31

 

2024

2023

2024

2023

2023

 
 
 
 
 
 

Income from voyages and related services

3,494.6

2,683.9

1,932.6

1,309.6

5,162.2

Cost of voyages and related services

 
 
 
 
 

Operating expenses and cost of services

(2,214.1)

(1,913.6)

(1,133.3)

(973.9)

(3,885.1)

Depreciation

(532.8)

(795.4)

(275.1)

(414.9)

(1,449.8)

Impairment of assets

 
 
 
 

(2,034.9)

Gross profit (loss)

747.7

(25.1)

524.2

(79.2)

(2,207.6)

 
 
 
 
 
 

Other operating income

25.6

1.9

19.6

(8.2)

14.4

Other operating expenses

(0.6)

(10.1)

(0.6)

(6.5)

(29.3)

General and administrative expenses

(133.8)

(145.5)

(73.0)

(71.4)

(280.7)

Share of loss of associates

(4.0)

(2.9)

(1.9)

(2.5)

(7.8)

 
 
 
 
 
 

Results from operating activities 

634.9

(181.7)

468.3

(167.8)

(2,511.0)

 
 
 
 
 
 

Finance income

61.2

82.1

22.5

37.7

142.2

Finance expenses

(224.9)

(237.2)

(115.9)

(142.0)

(446.7)

 

Net finance expenses

(163.7)

(155.1)

(93.4)

(104.3)

(304.5)

 
 
 
 
 
 

Profit (loss) before income taxes

471.2

(336.8)

374.9

(272.1)

(2,815.5)

 
 
 
 
 
 

Income taxes

(6.3)

66.0

(2.1)

59.4

127.6

 

Profit (loss) for the period

464.9

(270.8)

372.8

(212.7)

(2,687.9)

 
 
 
 
 
 

Attributable to:

 
 
 
 
 

Owners of the Company

461.6

(274.6)

371.3

(215.1)

(2,695.6)

Non-controlling interests

3.3

3.8

1.5

2.4

7.7

Profit (loss) for the period

464.9

(270.8)

372.8

(212.7)

(2,687.9)

 
 
 
 
 
 

Earnings (loss) per share (US$)

 
 
 
 
 

Basic earnings (loss) per 1 ordinary share

3.84

(2.29)

3.08

(1.79)

(22.42)

Diluted earnings (loss) per 1 ordinary share

3.83

(2.29)

3.08

(1.79)

(22.42)

 

Weighted average number of shares 
for earnings (loss) per share calculation:

 
 
 
 
 

Basic

120,324,186

120,182,399

120,341,086

120,195,365

120,213,031

Diluted

120,454,311

120,182,399

120,456,342

120,195,365

120,213,031

 

 

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

(U.S. dollars in millions)

 

Six months ended
June 30

Three months ended
June 30

Year ended
December 31

 

2024

2023

2024

2023

2023

Cash flows from operating activities

 
 
 
 
 

Profit (loss) for the period

464.9

(270.8)

372.8

(212.7)

(2,687.9)

Adjustments for:

 
 
 
 
 

Depreciation and amortization

538.6

808.7

278.0

421.5

1,471.8

Impairment loss

 
 
 
 

2,063.4

Net finance expenses 

163.7

155.1

93.4

104.3

304.5

Share of losses and change in fair value of investees

4.0

2.2

1.9

1.8

6.5

Capital loss (gain), net

(25.5)

7.4

(19.5)

17.2

(10.9)

Income taxes

6.3

(66.0)

2.1

(59.4)

(127.6)

Other non-cash items

3.0

9.7

1.5

3.4

18.9

 

1,155.0

646.3

730.2

276.1

1,038.7

 
 
 
 
 
 

Change in inventories

(8.4)

16.6

9.6

15.0

11.4

Change in trade and other receivables

(447.0)

176.9

(210.8)

33.7

242.7

Change in trade and other payables including contract liabilities

331.8

(95.9)

198.5

(4.2)

(95.1)

Change in provisions and employee benefits

27.3

2.9

24.1

1.5

15.9

 

(96.3)

100.5

21.4

46.0

174.9

 
 
 
 
 
 

Dividends received from associates

1.2

1.5

 

1.4

2.3

Interest received

39.8

88.0

17.8

38.5

133.8

Income taxes received (paid)

3.2

(316.1)

7.4

(15.4)

(329.7)

 
 
 
 
 
 

Net cash generated from operating activities

1,102.9

520.2

776.8

346.6

1,020.0

 
 
 
 
 
 

Cash flows from investing activities

 
 
 
 
 

Proceeds from sale of tangible assets, intangible assets
    and interest in investees

3.2

17.7

1.7

5.5

27.4

Acquisition and capitalized expenditures of tangible assets,
    intangible assets and interest in investees

(90.8)

(61.5)

(66.4)

(25.6)

(115.7)

Proceeds from sale (acquisition) of investment instruments, net

315.1

(583.4)

116.1

(422.3)

(138.2)

Loans granted to investees

(2.8)

(1.7)

(1.6)

 

(5.4)

Change in other receivables

15.4

(14.0)

7.7

(5.8)

3.2

Change in other investments (mainly deposits), net

 

1,982.7

(1.1)

581.8

2,005.2

Net cash generated from investing activities

240.1

1,339.8

56.4

133.6

1,776.5

Cash flows from financing activities

 
 
 
 
 

Repayment of lease liabilities and borrowings

(1,117.0)

(861.4)

(480.3)

(466.4)

(1,713.1)

Change in short term loans

 

(21.0)

 
 

(21.0)

Dividend paid to non-controlling interests

(3.7)

(7.5)

(3.3)

(0.6)

(8.9)

Dividend paid to owners of the Company

(27.7)

(769.2)

(27.7)

(769.2)

(769.2)

Interest paid

(221.6)

(182.7)

(117.9)

(95.9)

(380.7)

Net cash used in financing activities

(1,370.0)

(1,841.8)

(629.2)

(1,332.1)

(2,892.9)

 
 
 
 
 
 

Net change in cash and cash equivalents

(27.0)

18.2

204.0

(851.9)

(96.4)

Cash and cash equivalents at beginning of the period

921.5

1,022.1

687.9

1,892.6

1,022.1

Effect of exchange rate fluctuation on cash held

(4.7)

0.0

(2.1)

(0.4)

(4.2)

Cash and cash equivalents at the end of the period

889.8

1,040.3

889.8

1,040.3

921.5

 

RECONCILIATION OF NET INCOME TO ADJUSTED EBIT*

(U.S. dollars in millions)

 

Six months ended

 

Three months ended

June 30

 

June 30

 

2024

 

2023

 

2024

 

2023

 
 
 
 
 
 
 
 

Net income (loss)

465

 

(271)

 

373

 

(213)

Financial expenses, net

164

 

155

 

93

 

104

Income taxes

6

 

(66)

 

2

 

(59)

Operating income (EBIT) 

635

 

(182)

 

468

 

(168)

Non-cash charter hire expenses

0

 

1

 

0

 

0

Capital loss (gain), beyond the ordinary course of business

0

 

21

 

0

 

0

Expenses related to legal contingencies 

20

 

0

 

20

 

0

Adjusted EBIT

655

 

(160)

 

488

 

(147)

Adjusted EBIT margin

19 %

 

(6) %

 

25 %

 

(11) %


* The table above may contain slight summation differences due to rounding.

 
 
 
 
 
 
 
 
 
 
 
 
 

RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA*

(U.S. dollars in millions)

 

Six months ended

 

Three months ended

June 30

 

June 30

 

2024

 

2023

 

2024

 

2023

 
 
 
 
 
 
 
 

Net income (loss)

465

 

(271)

 

373

 

(213)

Financial expenses, net

164

 

155

 

93

 

104

Income taxes

6

 

(66)

 

2

 

(59)

Depreciation and amortization

539

 

809

 

278

 

422

EBITDA

1,173

 

627

 

746

 

254

Capital loss (gain), beyond the ordinary course of business

0

 

21

 

0

 

21

Expenses related to legal contingencies

20

 

0

 

20

 

0

Adjusted EBITDA

1,193

 

648

 

766

 

275

Net income (loss) margin 

13 %

 

(10) %

 

19 %

 

(16) %

Adjusted EBITDA margin

34 %

 

24 %

 

40 %

 

21 %


* The table above may contain slight summation differences due to rounding.

 
 
 
 
 
 
 
 
 

RECONCILIATION OF NET CASH GENERATED FROM OPERATING ACTIVITIES TO FREE CASH FLOW

(U.S. dollars in millions)

 

Six months ended

 

Three months ended

June 30

 

June 30

 

2024

 

2023

 

2024

 

2023

 
 
 
 
 
 
 
 

Net cash generated from operating activities

1,103

 

520

 

777

 

347

Capital expenditures, net 

(88)

 

(57)

 

(65)

 

(26)

Free cash flow

1,015

 

463

 

712

 

321

 
 
 
 
 
 
 
 

 

See disclosure regarding “Use of Non-IFRS Financial Measures.”
Operating income (EBIT) for the second quarter was $468 million. A reconciliation to Adjusted EBIT is provided in the tables below.
The Company does not provide IFRS guidance because it cannot be determined without unreasonable effort. See disclosure regarding “Use of Non-IFRS Measures in the Company’s 2024 Guidance.”
The number of shares used to calculate the diluted earnings per share is 120,456,342. The number of outstanding shares as of June 30, 2024 was 120,354,980.

Logo – https://mma.prnewswire.com/media/1933864/ZIM_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/zim-reports-financial-results-for-the-second-quarter-of-2024-raising-full-year-2024-guidance-302225247.html

SOURCE ZIM Integrated Shipping Services Ltd.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Marvion Inc. Subsidiary Signs Agreement with Engineering Firm for Construction of New State-of-the-Art Warehouse Facility

Published

on

By

HONG KONG, Nov. 14, 2024 /PRNewswire/ — Marvion Inc. (OTC: MVNC) is pleased to announce that its subsidiary United Warehouse Management Limited has officially signed a quotation agreement with Star Warehouse Engineering Limited for the construction of a new, state-of-the-art warehouse facility. The new warehouse will be strategically located to support the company’s growing logistics and storage operations, underscoring MVNC’s commitment to scaling up its infrastructure to meet the increasing market demand.

The new warehouse will feature two floors, each spanning 18,000 square feet, for a total floor area of 36,000 square feet. This expansion is set to enhance MVNC’s storage capabilities, streamline supply chain efficiency, and optimize logistics operations to better serve its expanding customer base.

Strategic Infrastructure Investment to Drive Long-Term Growth

This significant investment marks a crucial step in MVNC’s long-term strategic plan to solidify its position as a leader in the logistics and storage services sector. The new warehouse will not only bolster the company’s existing storage capacity but also enable the integration of advanced logistics and storage technologies. The facility will be equipped with modern automated systems with artificial intelligence engine to support high-volume inventory management and faster turnaround times, further strengthening MVNC’s competitive advantage in the region.

Commenting on this milestone, Mr. Chan Sze Yu, CEO of Marvion Inc., said:
“This new warehouse is a testament to our commitment to expanding our infrastructure to meet the ever-growing demand in the logistics industry. By investing in this state-of-the-art facility, we are positioning Marvion to better serve our clients and seize emerging opportunities in the market. This project will not only enhance our operational efficiency but also increase our capacity to support strategic partners like FedEx, SF Express, and other key clients.”

Supporting Sustainable Growth in the Asia-Pacific Region

Aligned with MVNC’s sustainability goals, the new facility will incorporate environmentally friendly design elements, such as energy-efficient lighting systems and optimized insulation to reduce energy consumption. These initiatives underscore MVNC’s dedication to promoting sustainable business practices while driving growth.

The construction is scheduled to begin in Q4 2024, with completion expected by the end Q2 2025. The new facility is projected to generate significant operational synergies, contributing to the company’s continued revenue growth and profitability.

About Marvion Inc.

Marvion Inc. (OTC: MVNC) is a leading logistics and warehousing solutions provider based in Hong Kong. The company specializes in offering one-stop transport and storage services to business clients, leveraging advanced digital technologies and efficient inventory management systems.

Company Website: www.unitedksk.com

View original content:https://www.prnewswire.com/news-releases/marvion-inc-subsidiary-signs-agreement-with-engineering-firm-for-construction-of-new-state-of-the-art-warehouse-facility-302305403.html

SOURCE Marvion Inc.

Continue Reading

Technology

American Liver Foundation Hosts the 33rd Annual Irwin M. Arias Symposium

Published

on

By

Virtual and in-person event, Bridging Basic Science and Liver Disease, brings together hundreds of leading biomedical scientists and physicians from across the globe 

FAIRFIELD, N.J., Nov. 14, 2024 /PRNewswire/ — American Liver Foundation is excited to host its 33rd annual Irwin M. Arias Symposium, Bridging Basic Science and Liver Disease, on Wednesday, November 20th from 9AM to 5PM ET. Hundreds of leading biomedical scientists and physicians around the world will come together for this prestigious hybrid, in-person and virtual, one-day event. Each presentation highlights remarkable scientific advances in basic biology and engineering while also providing cutting edge research for a better understanding of liver diseases and the best treatment options available today.

Bridging Basic Science & Liver Disease brings together leading biomedical scientists and physicians from across globe

This informative symposium features 10 unique plenary talks from renowned researchers such as Presidential Medal of Freedom recipient and physician-geneticist Francis S. Collins, MD, PhD, who led the Human Genome Project and discovered the genes causing several genetic diseases. He also served under three Presidents as the Director of the U.S. National Institutes of Health (NIH), the largest supporter of biomedical research in the world. He is currently leading a bold effort to eradicate Hepatitis C throughout the United States. Anne Carpenter, PhD, is the Senior Director of the Imaging Platform and an Institute Scientist at the Broad Institute of MIT and Harvard. She was included on the Top 100 list of AI leaders for her team’s open-source CellProfiler software that is used by thousands of biologists worldwide and their Cell Painting assay that has been adopted throughout the pharma industry to accelerate drug discoveries. There will also be a collection of three-minute ‘MicroTalks’ delivered by trainee scientists.

“This unique one-day annual symposium is a must-attend event for scientists interested in exploring innovative, groundbreaking research conducted in labs and the therapeutic treatments eventually delivered in clinics across the country,” said Lorraine Stiehl, CEO, American Liver Foundation. “Over the past 33 years, research presented at this event has led to many advances in the diagnosis and treatment of virtually all liver diseases in children and adults. Dr. Irwin M. Arias, recognized throughout the world, has devoted his life’s work to advancing liver disease research, treatments and cures and we’re so grateful for his expertise. Liver patients everywhere have benefited from his preeminent work.”

Symposium co-chairs include Sangeeta Bhatia, MD, PhD, John J. and Dorothy Wilson Professor, Electrical Engineering and Computer Science and Institute of Medical Engineering and Science Department at MIT, and Wolfram Goessling, MD, PhD, Chief of Gastroenterology at Massachusetts General Hospital, Director of the Harvard-MIT Health Sciences & Technology at Harvard Medical School and a Professor of Medicine at Harvard Medical School. The overall programming has been designed to honor Dr. Arias’ founding commitment to ‘bridging’ the gap between the academic, industrial, and clinical research communities – even across disciplines.

“The burden of chronic liver diseases affects over 100 million people in the United States alone and is rapidly becoming a public health crisis,” said Dr. Goessling, Chief of Gastroenterology at Massachusetts General Hospital. “Unfortunately, we currently lack effective tools for prevention, diagnosis and treatment for many liver conditions, so it’s vitally important to connect basic science research with the ongoing needs prevalent in many clinics and the Arias Symposium provides this opportunity.”

“Significant gaps remain in the understanding of many liver diseases and the fundamental systems involved in normal and pathological liver function,” said Dr. Bhatia, John J. and Dorothy Wilson Professor at MIT’s Institute of Medical Engineering and Science Department. “This scientific conference bridges basic science and liver disease while also nurturing successful careers in basic and translational liver research. The Arias Symposium allows us all to come together to share our research, encourage new trainees to learn more about liver disease and offers everyone one-day to learn what’s new and engaging in the world of liver research and science.”

The symposium is open to researchers at every stage of their careers, and they are encouraged to share perspectives from their academic, industrial, and clinical research settings. In-person attendees will benefit from a poster session and networking opportunities with plenary speakers and other attendees. Breakfast, lunch, and a networking reception will also be provided to in-person attendees. Registration is free for all trainees (postdocs, fellows, grads, students, undergrads, etc.). Registration is $50 for in-person attendees other than trainees. Virtual attendance is free but does require registration. Register here for this informative event.

This one-day virtual program will include topics such as:  

It’s Time to Eliminate Hepatitis C in the U.S. Francis Collins, MD, PhD – National Institutes of Health (VIRTUAL)Post-Transplant Alloimmune Hepatitis – What do we know and What’s New Udeme Ekong, MD, MPH, FAASLD – Georgetown University Detecting Liver Phenotypes and Toxicity Using Cell Image Data Anne Carpenter, PhD – Broad Institute of MIT and HarvardSpatial Clonal Tracing in Solid Tissues Fernando Camargo, PhD – Massachusetts Institute of TechnologyHolistic Multi-Scale Molecular Imaging of Human Organs Kwanghun Chung, PhD – Boston Children’s HospitalCell Identity Conversion – Liver Regeneration and Cell Therapy Lijian Hui, PhD – Shanghai Institutes for Biological SciencesDeveloping Cirrhosis Therapies: The Three Grand Challenges Quin Wills, MD, PhD – Ochre BioPediatric Liver Tumors: Clinical Context and Opportunities for Collaboration Allison O’Neill, MD – Dana-Farber Cancer InstituteUnderstanding How the Organism Monitors Liver Sufficiency to Properly Time RegenerationKristin Knouse, MD, PhD – Massachusetts Institute of TechnologyCellular and Molecular Drivers of Liver Cancer Response to ImmunotherapyMiriam Merad, MD, PhD – Mount Sinai School of Medicine

For the full agenda, list of speakers, and registration, please visit alfevents.org/ariassymposium.  

In addition to the Arias Symposium, American Liver Foundation offers a research awards program in three categories, Liver Scholar Award, Postdoctoral Research Fellowship Award, and Pilot Research Awards that recently funded eight highly innovative projects into these rare diseases – PSC, AIH and BA. Since 1979, ALF’s research awards program has provided more than $28 million in research funding. Over 850 qualified scientists and physicians have pursued research careers in liver biology, disease and treatment because they received these grants early in their careers. Learn more at liverfoundation.org/research.

About the American Liver Foundation
American Liver Foundation (ALF) is a national community of patients, caregivers and medical professionals dedicated to helping people improve their liver health. Providing guidance and life-saving resources, we are a beacon for the 100 million Americans affected by liver disease. We advocate for patients and families, fund medical research and educate the public about liver wellness and disease prevention. We bring people together through our educational programs and events and create a network of support that lasts a lifetime. ALF is the largest organization focused on all liver diseases and the trusted voice for patients and families living with liver disease. For more information visit www.liverfoundation.org or call: 1 800 GO LIVER (800-465-4837).

Media Contacts:                   
Julie Kimbrough
JKimbrough@liverfoundation.org              
Direct dial: 646-737-9409   
Karla Thomas     
Direct dial: 773.575.9477        

Facebook
X
LinkedIn
YouTube
Instagram

View original content to download multimedia:https://www.prnewswire.com/news-releases/american-liver-foundation-hosts-the-33rd-annual-irwin-m-arias-symposium-302305187.html

SOURCE American Liver Foundation

Continue Reading

Technology

Avantor® Opens New Bridgewater Innovation Center Focused on Solving Life Science’s Biggest Challenges

Published

on

By

RADNOR, Pa., Nov. 14, 2024 /PRNewswire/ — Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the opening of its new flagship Bridgewater Innovation Center. The state-of-the-art research and development facility, located in Bridgewater, NJ, is part of Avantor’s network of 13 research and innovation centers across the globe.

Avantor’s new Bridgewater Innovation Center spans 60,000 square feet, doubling its previous laboratory and pilot plant capacity. Purpose-designed for collaborative work, the center houses spaces for upstream and downstream process development, dedicated analytical testing labs, and a viral vector laboratory. An expanded pilot plant supports scale-up simulations, enabling rapid customization across the entire bioprocessing workflow.

“Our new Bridgewater Innovation Center is twice the size of our previous facility and adds capacity, talent and capabilities to support the growing demands for monoclonal antibodies, cell and gene therapy and mRNA workflows,” said Michael Stubblefield, President and CEO of Avantor. “Working side-by-side with customers in our network of innovation centers across the globe enables us to power science at every step to deliver life-changing therapies faster, and more cost effectively.”

The Bridgewater Innovation Center allows Avantor to optimize and accelerate biomanufacturing processes at scale; resulting in faster problem solving, streamlined knowledge exchange, and strategic co-innovation. Staffed with Ph.D. scientists, bioengineers, biologists, and process engineers, this center enhances both capacity and expertise to support customers’ needs. The facility also supports Avantor’s sustainability goals, reinforcing the Company’s commitment to environmental responsibility.

For more information about the Bridgewater Innovation Center, visit: https://www.avantorsciences.com/us/en/about/innovation-in-biopharma/avantor-bridgewater-innovation-center

About Avantor
Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedInX (Twitter) and Facebook.

Global Media Contact
Eric Van Zanten
Head of External Communications
Avantor
610-529-6219
Eric.VanZanten@avantorsciences.com

Investor Relations Contact
Christina Jones
Vice President, Investor Relations
Avantor
805-617-5297
Christina.Jones@avantorsciences.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-opens-new-bridgewater-innovation-center-focused-on-solving-life-sciences-biggest-challenges-302304526.html

SOURCE Avantor and Financial News

Continue Reading

Trending